Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Immuneering will present a poster at the 41st Annual SITC meeting (November 4-8, 2026, Phoenix) showing that atebimetinib enhances PD-1 checkpoint blockade in RAS mutant preclinical tumor models. The findings provide mechanistic support for a planned Phase 2 study of atebimetinib combined with PD-1 blockade in lung cancer patients.
Key figures
- Drug Name
- atebimetinib
- Phase Of Trial
- Phase 2
- Conference
- 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
- Abstract number
- 377
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.